Anti-angiogenic peptides for cancer treatment

A peptide or its derivative of the structure:

• Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp (hereinafter referred as {4}),
• or
• Trp-Pro-Gly-Asn-Ile-Asp-Gly-Asp-Pro-Asn-Arg (hereinafter referred as {4′}),
• or
• Tyr-Thr-Met-Asn-Pro-Arg-Lys-Leu-Phe-Asp-Tyr (hereinafter referred as {5}),
• or
• Tyr-Asp-Phe-Leu-Lys-Arg-Pro-Asn-Met-Thr-Tyr (hereinafter referred as {5′}),
• or
• X-{4}-Y
• or
• X-{4′}-Y
• or
• X-{5}-Y
• or
• X-{5′}-Y
• or
• X-{4}-Ala-{5}-Y
• or
• X-{4′}-Ala-{5′}-Y
• or
• X-{5}-Ala-{4}-Y
• or
• X-{5}-Ala-{4}-Y
• or
• X-{4}-Cys-{5′}-Y
• or
• X-{4′}-Cys-{5′}-Y
• or
• X-{5}-Cys-{4}-Y
• or
• X-{5′}-Cys-{4′}-Y
• or
• X-{4}-(Gly-Gly-Gly-Ser)n-{5}-Y
• or
• X-{4′}-(Gly-Gly-Gly-Ser)n-{5′}-Y
• or
• X-{5}-(Gly-Gly-Gly-Ser)n-{4}-Y
• or
• 12
• or
• 13
• or
• 14
• or
• 15
• or
• 16
• or
• 17
• or
• 18
• or
• 19
• wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);
• wherein X is Acetyl group or other customary N-terminal protecting groups;
• wherein Y is amine, ethylamine, or other customary C terminal protecting groups;
• wherein n=1 to 3.